16. Clinical failure.

Intervention/Comparison	Outcome	Illustrative comparative risks (95% CI)		Relative effect: risk ratio (95% CI)	Number of participants (studies)	Certainty of the evidence (GRADE)	Comments: overview authors' assessment of the certainty of evidence
		Assumed risk	Corresponding risk
		With comparator	With intervention
Addition of IV SABA to inhaled SABA (Travers 2012a)	Clinical failure	933 per 1000	354 per 1000 (177 to 728)	0.38 (0.19 to 0.78)	29 (1)	Moderate	One point deducted as data contributed by only 1 study
IV SABA vs IV aminophylline for acute asthma (Travers 2012b)	Clinical failure	303 per 1000 with SABA	303 per 1000 (145 to 630) with aminophylline	1.00 (0.48 to 2.08)	66 (1)	Low	Certainty downgraded due to very serious imprecision

CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; IV: Intravenous; SABA: short‐acting beta2‐agonist.